

NY-ESO-1 Antibody (internal region)
Peptide-affinity purified goat antibody
Catalog # AF2906a**Specification**

NY-ESO-1 Antibody (internal region) - Product Information

Application	E
Primary Accession	P78358
Other Accession	NP_001318.1 , 1485
Predicted	Human
Host	Goat
Clonality	Polyclonal
Concentration	0.5 mg/ml
Isotype	IgG
Calculated MW	17992

NY-ESO-1 Antibody (internal region) - Additional Information**Gene ID** 1485;246100**Other Names**

Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, CT6.1, L antigen family member 2, LAGE-2, CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A

Dilution

E~~N/A

Format

0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

NY-ESO-1 Antibody (internal region) is for research use only and not for use in diagnostic or therapeutic procedures.

NY-ESO-1 Antibody (internal region) - Protein Information**Name** CTAG1A**Synonyms** CTAG, CTAG1, ESO1, LAGE2, LAGE2A**Cellular Location**

Cytoplasm

Tissue Location

Expressed in testis and ovary and in a wide variety of cancers. Detected in uterine myometrium. Expressed from 18 weeks until birth in human fetal testis. In the adult testis, is strongly expressed in spermatogonia and in primary spermatocytes, but not in post-meiotic cells or in testicular somatic cells (at protein level)

NY-ESO-1 Antibody (internal region) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

NY-ESO-1 Antibody (internal region) - Images**NY-ESO-1 Antibody (internal region) - References**

Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant. Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnajatic S, Old L, Pavlick AC, Bhardwaj N. J Immunol. 2008 Jul 1;181(1):776-84. PMID: 18566444